Loading...
LRMR logo

Larimar Therapeutics, Inc.NasdaqGM:LRMR 주식 보고서

시가총액 US$347.6m
주가
US$3.53
US$15.88
77.8% 저평가 내재 할인율
1Y82.9%
7D-13.9%
포트폴리오 가치
​
보기

Larimar Therapeutics, Inc.

NasdaqGM:LRMR 주식 리포트

시가총액: US$347.6m

Larimar Therapeutics (LRMR) 주식 개요

라리마 테라퓨틱스는 임상 단계의 생명공학 기업으로, 새로운 세포 투과 펩타이드 기술 플랫폼을 사용하여 희귀 질환 치료제를 개발하는 데 주력하고 있습니다. 자세히 보기

LRMR 펀더멘털 분석
스노우플레이크 점수
가치 평가1/6
미래 성장5/6
과거 실적0/6
재무 건전성6/6
배당0/6

강점

수익은 매년 56.13% 증가할 것으로 예상됩니다.

위험 분석

수익이 USD$1m 미만입니다($0)

지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.

지난 1년 동안 주주가 크게 희석되었습니다.


LRMR Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Larimar Therapeutics, Inc. 경쟁사

가격 이력 및 성과

Larimar Therapeutics 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$3.53
52주 최고가US$6.42
52주 최저가US$1.80
베타0.91
1개월 변동-26.61%
3개월 변동13.50%
1년 변동82.90%
3년 변동-3.42%
5년 변동-60.73%
IPO 이후 변동-71.30%

최근 뉴스 및 업데이트

분석 기사 • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 16

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Summary Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. With $175.4m cash runway into Q4-26 and multiple near-term catalysts, LRMR offers asymmetric risk-reward, targeting a 3-5x return if milestones are met. Read the full article on Seeking Alpha

Recent updates

분석 기사 • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 16

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Summary Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. With $175.4m cash runway into Q4-26 and multiple near-term catalysts, LRMR offers asymmetric risk-reward, targeting a 3-5x return if milestones are met. Read the full article on Seeking Alpha
분석 기사 • May 28

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Summary Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025. Accelerated Approval BLA filing of nomlabofusp for patients with Friedreich's Ataxia might be possible 2nd half of 2025 on basis of a surrogate biomarker endpoint of FXN protein levels. Read the full article on Seeking Alpha
분석 기사 • Dec 18

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 07

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Summary Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025. Additionally, CTI-1601 has multiple FDA and EU designations, potentially expediting its development and approval process. Despite competition risks, LRMR's unique approach and sufficient resources make it a speculative "Buy" for investors aware of inherent biotech risks. Read the full article on Seeking Alpha
분석 기사 • Aug 09

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 15

Larimar Therapeutics: More Data Still Needed

Summary Larimar Therapeutics' stock has surged 50% after its FA therapy was selected for FDA's START program, aiming for a BLA filing in 2H25. Its lead candidate Nomlabofusp is a protein replacement therapy for Friedreich's ataxia, competing with Biogen's Skyclarys and other potential treatments. Larimar has enough cash to fund operations until 2026, with analyst optimism and a timeline to potentially beat competitors to the market. Can the recent rally in the shares continue? A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 31

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by 2030. Interim data from the ongoing phase 2 open-label study, using nomlabofusp for the treatment of patients with Friedreich's Ataxia, expected Q4 of 2024. Nomlabofusp for the treatment of patients with Friedreich's Ataxia selected as part of the FDA pilot program known as START, which is intended to accelerate the development of drugs that target rare unmet medical needs. Read the full article on Seeking Alpha
분석 기사 • Nov 13

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • May 19

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
분석 기사 • Feb 02

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 20

Laramar Therapeutics issued patent for lead pipeline candidate

Larimar Therapeutics (NASDAQ:LRMR) has been granted a composition of matter patent covering CTI-1601, its lead pipeline candidate for Friedreich’s ataxia. The patent provides coverage through at least July 2040. CTI-1601, currently in phase 1, has Fast Track and Orphan Drug designation from the US FDA. The company plans to begin a phase 2 trial for CTI-1601 by the end of the year. Seeking Alpha's Quant Rating views Larimar (LRMR) as a strong buy with high marks for momentum and revisions.
Seeking Alpha • Sep 14

Larimar Therapeutics prices ~$70M stock offering

Larimar Therapeutics (NASDAQ:LRMR) has priced of an underwritten offering of 22,225,000 shares of common stock at $3.15 per share. Underwriters have been granted a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price. Gross proceeds to Larimar (LRMR) are expected to be ~$70M. The offering is expected to close around Sep 16, 2022. The biotech company also received FDA clearance to initiate the 25mg cohort of a Phase 2 Dose exploration trial of its lead compound, CTI-1601, in Friedreich's ataxia patients. It plans to begin the Phase 2 trial in Q4 2022, with top-line data expected in 2H 2023. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia who are unable to produce enough of this essential protein. LRMR shares have gained 2% pre-market on the news
분석 기사 • Sep 02

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

Larimar Therapeutics GAAP EPS of -$0.47

Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.47. Cash and marketable debt securities at June 30, 2022 of $54.9 million provides projected cash runway through the third quarter of 2023
분석 기사 • Mar 21

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Dec 18

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Feb 08

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

주주 수익률

LRMRUS BiotechsUS 시장
7D-13.9%-4.9%-1.0%
1Y82.9%28.1%23.3%

수익률 대 산업: LRMR은 지난 1년 동안 28.1%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: LRMR은 지난 1년 동안 23.3%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is LRMR's price volatile compared to industry and market?
LRMR volatility
LRMR Average Weekly Movement21.8%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

안정적인 주가: LRMR의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: LRMR의 주간 변동성은 지난 1년간 16%에서 22%로 증가했습니다.

회사 소개

설립직원 수CEO웹사이트
n/a71Carole Ben-Maimonwww.larimartx.com

라리마 테라퓨틱스는 임상 단계의 생명공학 회사로 새로운 세포 침투 펩타이드 기술 플랫폼을 사용하여 희귀 질환 치료제를 개발하는 데 주력하고 있습니다. 주요 제품 후보로는 희귀하고 진행성이며 치명적인 질환인 프리드리히 운동실조증 치료를 위한 OLE 임상 2상 시험 중인 CTI-1601이 있습니다. 이 회사는 펜실베이니아주 발라 신위드에 본사를 두고 있습니다.

Larimar Therapeutics, Inc. 기초 지표 요약

Larimar Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
LRMR 기초 통계
시가총액US$347.60m
순이익 (TTM)-US$166.00m
매출 (TTM)n/a
0.0x
주가매출비율(P/S)
-2.2x
주가수익비율(P/E)

LRMR는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
LRMR 손익계산서 (TTM)
매출US$0
매출원가US$0
총이익US$0
기타 비용US$166.01m
순이익-US$166.00m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)-1.59
총이익률0.00%
순이익률0.00%
부채/자본 비율0%

LRMR의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/20 01:48
종가2026/05/20 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Larimar Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Joel BeattyBaird
null nullBaird
Christopher ChenBaird